May enhance blood-glucose-lowering effect & increase susceptibility to hypoglycaemia w/ oral anti-diabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamides. May reduce the blood-glucose-lowering effect w/ corticosteroids; danazol, diazoxide, diuretics, glucagon, INH, estrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. May potentiate or weaken
the blood glucose lowering effect w/ β-blockers, clonidine lithium salts or alcohol. Hypoglycemia followed by hyperglycemia w/ pentamidine.
Reduced or absent adrenergic counter regulation w/ sympatholytics eg, β-blockers,
clonidine, guanethidine & reserpine.